Insider · CIK 0001356256

Myers Scott Dunseth

Reports to the SEC for 9 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001356256

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-16	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+57.1K sh	—	—	395,895
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−28.5K sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−22.5K sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−22.5K sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−45K sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORPU Disposition from Tender	Director	UDisposition from Tender	−3,800 sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORPD Disposition to Issuer	Director	DDisposition to Issuer	−31.2K sh	—	—	0
2026-02-10	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.9K sh	—	—	0
2025-08-22	DVAXDYNAVAX TECHNOLOGIES CORPP Purchase	Director	PPurchase	+3,800 sh	$10.82	+$41.1K	35,004
2025-06-17	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+57.6K sh	—	—	338,795
2025-06-11	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)A Award	Director	AAward	+28.5K sh	—	—	28,500
2025-06-11	DVAXDYNAVAX TECHNOLOGIES CORPA Award	Director	AAward	+5,758 sh	—	—	31,204
2025-04-30	ZNTLZentalis Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+21K sh	$1.40	+$29.4K	281,192
2024-11-13	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+260K sh	—	—	260,192
2024-05-23	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2024-05-23	DVAXDYNAVAX TECHNOLOGIES CORPA Award	Director	AAward	+5,357 sh	—	—	25,446
2024-03-11	Harpoon Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−22.7K sh	—	—	0
2024-03-11	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,600 sh	—	—	0
2024-03-11	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,033 sh	—	—	0
2024-01-01	Harpoon Therapeutics, Inc.A Award	Director	AAward	+2,048 sh	—	—	22,666
2023-11-27	Harpoon Therapeutics, Inc.A Award	Director	AAward	+5,000 sh	—	—	20,618
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	—	—	0
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−87.5K sh	$0.93	−$81.4K	0
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	—	—	0
2023-10-01	Harpoon Therapeutics, Inc.A Award	Director	AAward	+5,797 sh	—	—	15,618
2023-07-01	Harpoon Therapeutics, Inc.A Award	Director	AAward	+35.6K sh	—	—	98,215
2023-06-22	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)A Award	Director	AAward	+46K sh	—	—	46,000
2023-05-26	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2023-05-26	DVAXDYNAVAX TECHNOLOGIES CORPA Award	Director	AAward	+5,357 sh	—	—	20,089
2023-04-12	VRDNViridian Therapeutics, Inc.\DEP Purchase	Director, Chief Executive Officer	PPurchase	+4,000 sh	$25.37	+$101K	259,500
2023-04-01	Harpoon Therapeutics, Inc.A Award	Director	AAward	+34.9K sh	—	—	62,581
2023-03-13	VRDNViridian Therapeutics, Inc.\DEP Purchase	Director, Chief Executive Officer	PPurchase	+5,500 sh	$29.15	+$160K	255,500
2023-02-06	VRDNViridian Therapeutics, Inc.\DEA Award	Director, Chief Executive Officer	AAward	+250K sh	—	—	250,000
2023-02-06	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+1M sh	—	—	1,000,000
2023-01-02	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+87.5K sh	—	—	87,500
2022-06-22	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,334
2022-05-26	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)A Award	Director	AAward	+16.9K sh	—	—	16,875
2022-05-26	DVAXDYNAVAX TECHNOLOGIES CORP · Restricted Stock UnitA Award	Director	AAward	+4,018 sh	—	—	4,018
2022-01-03	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−67K sh	—	—	0
2021-10-25	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)A Award	Director	AAward	+10.2K sh	—	—	10,167
2021-10-19	DVAXDYNAVAX TECHNOLOGIES CORP · Restricted Stock UnitA Award	Director	AAward	+10.7K sh	—	—	10,714
2021-10-19	DVAXDYNAVAX TECHNOLOGIES CORP · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2021-05-04	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)A Award	Director	AAward	+10.2K sh	—	—	10,167
2021-05-04	Harpoon Therapeutics, Inc.Director Stock Option (Right to Buy)A Award	Director	AAward	+10.2K sh	—	—	10,167
2021-05-03	Trillium Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+67K sh	—	—	67,000
2021-03-30	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2020-11-16	AMAG PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−1M sh	—	—	0

Recent filings

Accepted (ET)
Jun 184
Myers Scott Dunseth0001356256-26-000005
SEC(opens sec.gov)
Feb 104
Myers Scott Dunseth0001356256-26-000002
SEC(opens sec.gov)
Aug 254
Myers Scott Dunseth0001029142-25-000120
SEC(opens sec.gov)
Jun 184
Myers Scott Dunseth0001725160-25-000129
SEC(opens sec.gov)
Jun 134
Myers Scott Dunseth0001029142-25-000102
SEC(opens sec.gov)
Apr 304
Myers Scott Dunseth0001725160-25-000094
SEC(opens sec.gov)
Nov 134
Myers Scott Dunseth0001725160-24-000186
SEC(opens sec.gov)
May 284
Myers Scott Dunseth0000950170-24-065592
SEC(opens sec.gov)
Mar 114
Myers Scott Dunseth0000950170-24-029443
SEC(opens sec.gov)
Jan 34
Myers Scott Dunseth0000950170-24-000962
SEC(opens sec.gov)

Companies

Address

C/O ZENTALIS PHARMACEUTICALS, INC. 10275 SCIENCE CENTER DRIVE, SUITE 200

SAN DIEGO, CA, 92121